Literature DB >> 7198883

Plasma levels of ketamine and two of its metabolites in surgical patients using a gas chromatographic mass fragmentographic assay.

E F Domino, E K Zsigmond, L E Domino, K E Domino, S P Kothary, S E Domino.   

Abstract

Ketamine and two of its metabolites were determined up to 24 hours by a sensitive and specific gas chromatographic mass fragmentographic (GCMF) assay in the plasma of seven premedicated surgical patients. Each patient received ketamine in a dose between 2.0 and 2.2 mg/kg given intravenously over a 30-second period. Plasma levels of ketamine varied from 9,000 to 25,800 ng/ml 1 minute after injection to approximately 1,000 ng/ml when the patients began to recover consciousness. Within the next 24 hours, the patients had a complex logarithmic decline after injection. The data suggest rather complex pharmacokinetics with multiple compartments. Ketamine metabolites I and II were also found in the plasma over comparable periods of time. Ketamine metabolite I levels ranged from a high of 245 to 668 ng/ml within 30 minutes after ketamine administration to as low as 15 ng/ml 24 hours later. Ketamine metabolite II levels were lower with a peak of 515 ng/ml in approximately 60 minutes to 13 to 27 ng/ml 24 hours later. Recovery from anesthesia was related to the first two phases of rapid redistribution of ketamine. The plasma levels of the two ketamine metabolites were first detectable approximately 5 minutes after ketamine injection. Their relatively low levels throughout ketamine anesthesia and postanesthesia do not correlate with recovery from anesthesia. CSTRIP and NONLIN analysis indicated that a three-exponential equation best approximated the data obtained. It is concluded that a three-compartment open model best approximates ketamine pharmacokinetics in these patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7198883

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  37 in total

1.  Morphine, but not ketamine, decreases the ratio of Th1/Th2 in CD4-positive cells through T-bet and GATA3.

Authors:  Mei Gao; Jie Sun; Wenjie Jin; Yanning Qian
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

Review 2.  Glutamatergic model psychoses: prediction error, learning, and inference.

Authors:  Philip R Corlett; Garry D Honey; John H Krystal; Paul C Fletcher
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

3.  Ketamine induces toxicity in human neurons differentiated from embryonic stem cells via mitochondrial apoptosis pathway.

Authors:  Zeljko J Bosnjak; Yasheng Yan; Scott Canfield; Maria Y Muravyeva; Chika Kikuchi; Clive W Wells; John A Corbett; Xiaowen Bai
Journal:  Curr Drug Saf       Date:  2012-04

4.  The pharmacokinetics and pharmacodynamics of ketamine in dogs anesthetized with enflurane.

Authors:  I M Schwieger; F Szlam; C C Hug
Journal:  J Pharmacokinet Biopharm       Date:  1991-04

5.  Distinct effects of ketamine and acetyl L-carnitine on the dopamine system in zebrafish.

Authors:  Bonnie L Robinson; Melanie Dumas; Elvis Cuevas; Qiang Gu; Merle G Paule; Syed F Ali; Jyotshna Kanungo
Journal:  Neurotoxicol Teratol       Date:  2016-02-16       Impact factor: 3.763

6.  Individual differences in psychotic effects of ketamine are predicted by brain function measured under placebo.

Authors:  Garry D Honey; Philip R Corlett; Anthony R Absalom; Michael Lee; Edith Pomarol-Clotet; Graham K Murray; Peter J McKenna; Edward T Bullmore; David K Menon; Paul C Fletcher
Journal:  J Neurosci       Date:  2008-06-18       Impact factor: 6.167

7.  Effects of ketamine on brain function during response inhibition.

Authors:  M Steffens; C Neumann; A-M Kasparbauer; B Becker; B Weber; M A Mehta; R Hurlemann; U Ettinger
Journal:  Psychopharmacology (Berl)       Date:  2018-10-24       Impact factor: 4.530

8.  Acute ketamine administration alters the brain responses to executive demands in a verbal working memory task: an FMRI study.

Authors:  R A E Honey; G D Honey; C O'Loughlin; S R Sharar; D Kumaran; E T Bullmore; D K Menon; T Donovan; V C Lupson; R Bisbrown-Chippendale; P C Fletcher
Journal:  Neuropsychopharmacology       Date:  2004-06       Impact factor: 7.853

9.  Effects of ketamine on brain function during smooth pursuit eye movements.

Authors:  M Steffens; B Becker; C Neumann; A M Kasparbauer; I Meyhöfer; B Weber; M A Mehta; R Hurlemann; U Ettinger
Journal:  Hum Brain Mapp       Date:  2016-11       Impact factor: 5.038

10.  Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory.

Authors:  Rebekah A E Honey; Danielle C Turner; Garry D Honey; Sam R Sharar; D Kumaran; E Pomarol-Clotet; P McKenna; B J Sahakian; T W Robbins; P C Fletcher
Journal:  Neuropsychopharmacology       Date:  2003-11       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.